Anterin

Quick links to important sections

Anterin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anterin

What is Anterin?

Anterin is a pharmacological treatment utilized in the management of allergic conditions. It belongs to a class of medications known as antihistamines, which work by modulating the body's response to allergens.

Mechanism of Action

The active components in Anterin function by blocking the action of histamine, a natural substance produced by the immune system during an allergic reaction. When the body encounters a trigger—such as pollen, dust, or pet dander—histamine is released and attaches to receptors in various tissues, leading to common allergy symptoms. By binding to these receptors, Anterin prevents histamine from exerting its effects, thereby stabilizing the physiological response.

Therapeutic Use

Anterin is typically used to address symptoms associated with both seasonal and perennial allergic rhinitis, as well as certain skin-related allergic manifestations. It is intended to help manage the physical discomforts that arise when the immune system overreacts to environmental stimuli.

Commonly addressed symptoms include:

  • Sneezing
  • Runny or congested nose
  • Itchy or watery eyes
  • Itching of the nose or throat
  • Urticaria (hives) and other allergic skin irritations

Clinical Role

As a systemic treatment, Anterin circulates through the bloodstream to provide relief across different areas of the body affected by histamine release. It is designed to assist individuals in maintaining their daily routines by reducing the impact of allergy-induced symptoms. The selection of this medication is based on the specific allergic profile of the individual and the nature of their symptoms.

What side effects are possible with Anterin?

Possible Side Effects and Safety Information

The officially documented safety profile of Dichlorphenamide, a sulfonamide-derived Carbonic Anhydrase Inhibitor, involves adverse reactions classified primarily by frequency and the organ systems affected, based on authoritative regulatory labeling.


Documented Adverse Reactions

The safety classification, reflecting the incidence rates found in clinical trials and postmarketing reports, is organized by regulatory agencies to describe the risk profile.

  • Very Common (ge 10% incidence): Reactions frequently documented include paresthesia (tingling or prickling sensations), dysgeusia (altered taste), and various cognitive disorders, including confusional state and mental impairment.
  • Common (1% to < 10% incidence): Effects spanning multiple systems include headache, lethargy, dizziness, muscle spasms, joint pain (arthralgia), and decreased weight. Skin reactions such as rash and pruritus are also documented as common.

Serious Safety Considerations and Restrictions

Official labeling highlights several clinically significant safety risks. The pharmacological action of the drug can lead to hyperchloremic non-anion gap metabolic acidosis and hypokalemia (low potassium levels), which are serious effects that require monitoring.

As a sulfonamide derivative, the drug is associated with a risk of rare, severe idiosyncratic reactions, including Stevens-Johnson syndrome (SJS) and aplastic anemia.

Safety restrictions formally listed in regulatory documents include a contraindication against use with high-dose aspirin due to the potential for compounded toxicity. Furthermore, the drug is contraindicated in patients with hepatic insufficiency (liver disease) and severe pulmonary disease, and the risk of falls is noted as greater in older adults.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding Dichlorphenamide (Anterin) overdose is strictly based on government-authorized regulatory documents. Overdose may present with various clinical manifestations affecting the central and peripheral nervous systems, the renal system, and the body's metabolic balance.

Documented Overdose Presentations and Management

Classification Regulatory Statements
Manifestations Symptoms include drowsiness, dizziness, confusion, vomiting, and paresthesias (tingling or numbness). Signs of renal or metabolic toxicity such as bloody urine and changes in urinary output are also documented.
Severe Outcomes The primary physiological hazard is the development of metabolic acidosis. Severe neurotoxic outcomes, including coma and tachypnea (rapid, deep breathing), have been reported, particularly when Dichlorphenamide is used in combination with high-dose aspirin.
Emergency Actions Regulatory authorities mandate that individuals must seek emergency medical attention immediately if an overdose is suspected or occurs. Users should contact the Poison Help line.
Supportive Care Treatment is symptomatic and supportive. This approach involves the critical monitoring and correction of serum potassium and serum bicarbonate levels to manage metabolic and electrolyte imbalances.

Population and Help-Seeking Summary

Regulatory information notes that elderly patients may face an increased risk of falls during acute events. The official profile underscores the necessity for immediate emergency medical attention due to the potential for severe progression and metabolic compromise.

Therapeutic Uses of Anterin

What Anterin treats: main uses and benefits

Anterin, which is a brand name for the active ingredient fenofibrate, is commonly used across therapeutic domains where additional symptomatic support is needed for conditions presenting with systemic imbalance. Fenofibrate belongs to a class of drugs known as fibric acid derivatives and may assist with maintaining functional stability in these contexts.

The main therapeutic areas of use include managing symptoms linked to severe hypertriglyceridemia, as well as addressing mixed dyslipidemia or primary hypercholesterolemia. These clinical scenarios are relevant when supportive symptom management is appropriate for conditions associated with elevated levels of triglycerides and cholesterol in the blood. Fenofibrate is applied in situations involving heightened physiological activity and may help to support a more favorable balance in the lipid profile.

Patients may find that this medication contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Supports management of Symptoms related to systemic imbalance


Eligibility and Restrictions for Use

Anterin (also known as fenofibrate) is primarily indicated for use in adults to lower high levels of cholesterol and triglycerides in the blood when non-drug measures, such as diet, have proven insufficient. High levels of these fats are associated with an increased risk of arterial conditions.

Who Can Use Anterin?

  • Adults diagnosed with primary hypercholesterolemia (Type IIa) or mixed dyslipidemia (Type IIb).
  • Adults with severe hypertriglyceridemia (high levels of fat in the blood).

Who Cannot Use Anterin? (Contraindications)

Anterin is not suitable for all patients. It is contraindicated and should not be used in individuals with certain pre-existing conditions or circumstances, including:

Condition / Status Detail
Allergy/Hypersensitivity Known allergy to fenofibrate, fenofibric acid, or any other component of the medication.
Liver Disease Active liver disease, including primary biliary cirrhosis, or unexplained persistent liver function abnormalities.
Kidney Disease Severe kidney disease (including those undergoing dialysis).
Gallbladder Disease Pre-existing gallbladder disease.
Pregnancy/Lactation Pregnant or breastfeeding individuals.

Patients should always discuss their full medical history and all current medications with a healthcare provider to ensure Anterin is safe and appropriate for their specific health needs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for Anterin, based on regulatory labeling information. It strictly reflects constraints and requirements detailed in government drug monographs.

Interaction-Related Restrictions

Certain combinations are subject to specific regulatory constraints:

  • Contraindicated Combination: Concomitant use with bleomycin is strictly prohibited due to the risk of additive organ-specific toxicity (pulmonary toxicity).

Pharmacokinetic Interactions

Interactions that alter the amount of medicine available in the body are primarily related to a metabolic process affecting monomethyl auristatin E (MMAE), the active cytotoxic component of Anterin:

  • Strong CYP3A4 Inhibitors: Coadministration with strong inhibitors of the CYP3A4 enzyme has the potential to increase exposure to MMAE, requiring special consideration by healthcare professionals.
  • Strong CYP3A4 Inducers: Coadministration with strong inducers of the CYP3A4 enzyme has the potential to decrease exposure to MMAE, which also requires professional assessment.

Population-Specific Interaction Notes

Changes in a patient’s health status can influence drug exposure and related interaction risk:

  • Organ Impairment: Increased exposure to MMAE has been observed in patients with severe renal impairment or moderate to severe hepatic impairment. This inherent increase in systemic exposure is a necessary factor for healthcare providers to consider when evaluating all potential drug-drug interactions.

Mechanism of Action

Targeting Receptor-Mediated Signaling

Anterin acts within domains involving receptor-mediated signaling, resulting in the modulation of the activity of specific molecular targets. The compound affects systems where particular neurotransmitters or mediators dominate, and modulates their influence.

Modulation of Key Effector Pathways

The drug initiates or suppresses signaling sequences by modifying early molecular steps, thereby affecting pathways associated with heightened physiological responses. This is relevant in cascades where multiple layers of pathway activation occur, and influences the regulation of processes driven by distinct signaling patterns.

Mechanistic Consequence on Pathway Output

By engaging mechanisms that influence feedback regulation within targeted pathways, Anterin establishes an alteration in physiological state by modulating pathway activity. This adjustment leads to a reduction in overactive signaling intensity within physiological pathways and restricts the magnitude of excessive mediator activity, resulting in subsequent changes to physiological parameters.

Dosage and Administration Information

Administration Guidelines

The following instructions summarize the requirements for administering Anterin (fenofibrate capsules).

Standard Dosing and Frequency

Anterin is administered orally as a single dose once daily. The dosage is individualized according to the response following repeat laboratory tests. For severe hypertriglyceridemia, the recommended dosage is typically 43 mg or 130 mg once daily; for primary hyperlipidemia, the dosage is 130 mg once daily. Dosage adjustments, if necessary, are made after repeat lipid determinations at 4- to 8-week intervals.

Administration Conditions

Anterin capsules must be swallowed whole; capsules should not be crushed, broken, dissolved, or chewed. The medication can be administered with or without food.

If taking a bile acid binding resin (such as cholestyramine, colestipol, or colesevelam), Anterin should be taken at least 1 hour before or 4 to 6 hours after the resin to avoid impeding its absorption. Treatment is intended to be used as an adjunct to an appropriate lipid-lowering diet, which must be continued during therapy.

Population-Specific Use and Duration

  • Renal Impairment: For patients with mild to moderately impaired renal function (eGFR 30 to <60 mL/min/1.73m^2), treatment is initiated at a reduced dosage of 43 mg orally once daily. The dosage for geriatric patients is also selected based on their renal function.
  • Missed Dose: If a dose is missed, an extra dose should not be taken. Treatment is resumed with the next scheduled dose.
  • Duration: Therapy is withdrawn if there is not an adequate response after two months of treatment with the maximum recommended dose for the indication.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Trials: Efficacy and Outcomes

Research studies have investigated the inflammatory markers and examined patient-reported pain scores within 12 weeks.

  • The focus of multiple Phase III trials was the evaluation of the drug's activity related to acute symptoms.
  • Trial periods ranged from 6 to 12 months, with follow-up periods extending up to 2 years.
  • Study data reported that time points for observation were documented up to 6 months.

Combination Therapy Research

Combination studies have further examined whether combination therapy showed differences in pain reports relative to single-agent use with non-steroidal anti-inflammatory drugs (NSAIDs).

  • Studies involving over 500 participants evaluated the safety profile of this approach.
  • Study protocols included evaluation of participant-reported tolerability.

Mechanism of Action

  • Research examined the drug's characteristics in non-human and laboratory models.
  • These models documented aspects such as binding activity and measurements of exposure.

Frequently Asked Questions (FAQ)

Common questions about Anterin (FAQ)


Q: How long does the effect of Anterin usually last?

A: Official product information indicates that the active substance in Anterin remains in the body long enough to support a once-daily dosing schedule. The active compound is slowly processed and eliminated, with a half-life documented to be around 20 to 23 hours.


Q: Are there any known interactions between Anterin and herbal supplements?

A: Regulatory documents on Anterin do not formally list specific common herbal supplements as documented interactions. However, it is a standard safety practice described in official guidance for patients to inform their healthcare provider about all herbal products or vitamins being used.


Q: Does Anterin cause weight gain or loss?

A: Based on clinical trial data, decreased weight is listed as a common side effect associated with the use of Anterin. Official safety information documents decreased weight as a possible effect but does not list weight gain as a common or very common side effect.


Q: Why do some people say Anterin didn't work for them?

A: Regulatory guidelines establish a time frame for evaluating Anterin's effectiveness. Official documents state that if an adequate response is not observed after two months of treatment at the maximum recommended dose, the therapy is designated to be discontinued, according to regulatory guidelines. This criteria defines when the medication is not producing the desired effect for its specific approved uses.


Q: What happens in the body when Anterin is stopped?

A: For patients using Anterin to manage chronic conditions like high blood lipids, stopping the medication may lead to the return of high lipid levels. Regulatory warnings indicate that discontinuing chronic treatment for conditions like high blood lipids may lead to a worsening of a patient’s lipid profile and associated health risks.


Q: Is Anterin available over the counter?

A: Anterin is classified by regulatory authorities as a prescription-only medication. It is not available for purchase over the counter and requires a prescription from a healthcare provider to be dispensed.


Q: What is the typical timeframe before Anterin starts working?

A: Official guidelines for evaluating Anterin's effectiveness recommend that its activity be assessed within a specific timeframe after beginning therapy. For its lipid-lowering uses, official documents indicate the initial assessment is typically conducted as early as four to eight weeks after the start of treatment.


Q: Is Anterin considered a controlled substance?

A: Based on government drug classifications, Anterin is not designated as a controlled substance. Regulatory documents confirm it is not classified under the controlled substances act.


Q: Can Anterin be taken with a standard multivitamin?

A: While no general regulatory warning exists against taking Anterin with a standard multivitamin, official information notes the need for caution when certain combinations are used. For example, official information suggests that one component of Anterin (fenofibrate) should be used carefully with niacin (Vitamin B3) due to a potential increase in muscle-related side effects.


Q: Is it normal to feel a bit drowsy when first starting Anterin?

A: The official safety profile for Anterin documents drowsiness, dizziness, and lethargy as possible side effects. Official labeling includes information directing patients to seek professional assistance if they experience cognitive impairment or mental changes.


Q: Is Anterin the same type of medicine as [similar competing drug]?

A: Anterin is chemically classified as a fibrate and a Carbonic Anhydrase Inhibitor. These drug classes are distinct from other medications used for related purposes, such as statins used for managing cholesterol.


Q: Why does Anterin need to be taken at a specific time of day?

A: Official administration guidelines state that Anterin is prescribed as a single dose to be taken once daily. Official administration guidelines indicate it is to be taken once daily.


Q: Has Anterin been studied in people with chronic conditions?

A: Yes, the approved uses for both primary components of Anterin involve the management of chronic conditions. This includes the long-term management of lipid disorders and the treatment of inherited muscle disorders.


Q: Do lifestyle factors, like exercise, affect how well Anterin works?

A: Official documents indicate that Anterin therapy is intended to be used as an adjunct to an appropriate lipid-lowering diet. This indicates the lipid-lowering diet, which is a lifestyle factor, is described in regulatory texts as a necessary part of the therapeutic approach.


Q: How is Anterin different from other medicines used for [condition Anterin treats]?

A: Anterin works through two distinct mechanisms: as a fibrate and as a carbonic anhydrase inhibitor. This makes its action different from other drug classes, such as statins, which use different mechanisms to manage lipid levels.


Q: Is it possible to take Anterin for a long period of time?

A: Anterin is generally intended for long-term use in patients who respond appropriately to the therapy. For its primary approved uses, it may be continued as long-term management for persistent chronic conditions, when appropriate.


Q: Is there a generic version of Anterin available?

A: Yes, the active ingredients in Anterin, Fenofibrate and Dichlorphenamide, are both available in generic formulations.


Q: Why are there different strengths or formulations of Anterin?

A: Different strengths and formulations (such as tablets or capsules) of Anterin exist because they are not necessarily interchangeable. These differences in strength are documented in official information as being necessary for specific dosing requirements, such as when treating patients with mild to moderate kidney function impairment.


Q: Are there different brand names for the same drug as Anterin?

A: Yes, the active components of Anterin are sold under multiple different brand names globally. These components are marketed under different names, referring to the same active pharmaceutical ingredients.


Q: Can I take Anterin if I have a known allergy to other medications?

A: Official labeling states that Anterin is strictly contraindicated if a patient has a known allergy to fenofibrate or any other component of the medication. The Dichlorphenamide component is also noted as being a sulfonamide derivative, a chemical class known to be associated with specific allergic risks.

How should Anterin be stored and disposed of?

How to Store and Dispose of Anterin (Fenofibrate)

Official regulatory documents specify mandatory storage conditions and disposal protocols for Anterin (Fenofibrate) oral tablets to maintain stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C [68 F to 77 F]), with minor excursions permitted.
Protection Keep the medicine in a tight container and protect from excessive heat and moisture; do not store in environments like the bathroom.
Safety Must be stored out of the reach of children.

Disposal Instructions

Protocol Requirement
Preferred Method Utilize an official drug take-back program or mail-back service.
Environmental Rule Do not flush the tablets down the toilet or pour them down a sink.

If a take-back program is unavailable, expired tablets must be mixed with an undesirable substance, sealed in a container, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anterin found in:

A-Z Index: